Psoriasis relapse following biologic therapy: current status
10.35541/cjd.20230301
- VernacularTitle:生物制剂治疗银屑病后复发的研究现状
- Author:
Wenqiu WANG
1
;
Chengxin LI
;
Rui WANG
Author Information
1. 解放军医学院，北京 100853
- Publication Type:Journal Article
- Keywords:
Psoriasis;
Recurrence;
Biological agents;
Tumor necrosis factor inhibitors;
Interleukin inhibitors;
Patient care management;
Universal precautions
- From:
Chinese Journal of Dermatology
2025;58(11):1090-1095
- CountryChina
- Language:Chinese
-
Abstract:
Psoriasis is a chronic, recurrent, systemic, inflammatory disease. Over the past 20 years, with the development and application of biologics targeting tumor necrosis factor (TNF) or TNF receptors, interleukin-17A (IL-17A) or IL-17A receptors, IL-23, and others, significant progress has been made in the treatment of psoriasis. However, recurrence remains a major challenge in the management of psoriasis after discontinuation of biologic therapy or during maintenance treatment. This review summarizes the recurrence of psoriasis following biologic treatment and proposes comprehensive management recommendations to prevent its recurrence.
